We report a case of a 64-year-old woman who developed transfusion-dependent anemia after cardiac transplantation, the etiology of which was unknown after initial comprehensive evaluation. At the suggestion of the Transplant Infectious Diseases consultant, microbial agents with red blood cell tropism pertinent to this patient such as Parvovirus B 19 (B19V) were investigated. The B19V viral load by PCR in peripheral blood was >100 000 000 copies/ml and after treatment with intravenous immunoglobulin (IVIG), her anemia resolved. Here, we summarize the clinical and virologic characteristics, treatment, and outcome of fifteen cases of B19V-induced anemia in heart transplant recipients. Spontaneous recovery from anemia secondary to B19V has also been reported in some heart transplant recipients, possibly due to an absence of their B19V P-antigen receptor and/or reduction in their immunosuppression. Therefore, in heart transplant patients, B19V should be suspected early as a cause of severe anemia of unknown etiology. The extent that B19V-induced anemia is underdiagnosed in heart transplant recipients is unknown.
| INTRODUC TI ON
Parvoviridae (Parvum: Latin for small) are among the smallest known DNA-containing viruses that infect humans. Parvovirus B19 (B19V) is classified as a member of the Erythroparvovirus genus given its unique ability to infect red blood cells. B19V was observed initially as a small particle in serum in 1974 but was officially recognized as a member of the parvoviridae family in 1985. 1 The association of B19V with significant clinical disease was first made in 1981 as a cause of transient aplastic crisis in patients with sickle cell anemia.
B19V was subsequently recognized as the etiologic agent of a wide variety of disease manifestations depending on the immunologic and hematologic status of the host. In the immunocompetent host, B19V causes erythema infectiosum (EI), migratory polyarthropathy, papular-purpuric "gloves and socks" syndrome (PPGSS) and congenital infection resulting in fetal loss, hydrops fetalis, and neonatal anemia.
In immunocompromised patients or those with underlying hemolytic anemias, transient pure red cell aplastic crises have been described. 1 In addition, persistent B19V viremia associated with severe transfusion-dependent anemia in immunocompromised patients was recognized in the late 1980s. 2 B19V-induced anemia has been related to the virus particular tropism for erythrocytes partially mediated by the P antigen present in human erythroid progenitor cells. 3 However, the definitive entry of B19V into red blood cells requires the presence of two co-receptors in addition to the P antigen. 4, 5 In solid organ transplant (SOT) patients including heart recipients, only few cases of B19V induced anemia have been reported. 6 Although the etiology of anemia in heart transplant patients is multifactorial, B19V should be considered in any patient with persistently low hemoglobin, particularly below 8 g/dL and without an obvious etiology.
We report a case of a 64-year-old woman with a history of heart transplantation 5 years prior who presented to clinic complaining of severe fatigue. She was found to be severely anemic, work up was notable for B19V viremia and treatment with intravenous immunoglobulin (IVIG) led to her full recovery. We also reviewed the literature on published cases of B19V-induced anemia in heart transplant recipients and their outcome after treatment. 
| C A S E REP ORT

| RE VIE W OF THE LITER ATURE
A search for case-reports in English language medical literature via PubMed and ScienceDirect with the following <Mesh> terms: "heart transplant," "heart transplantation," "anemia," "refractory anemia," and "parvovirus B19" was performed. The first case of anemia secondary to B19V in a heart transplant patient was reported in 1993. 6 Since then only 15 additional heart transplant patients (including this case report) have been reported to have developed anemia, including transfusion-dependent anemia secondary to B19V. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] References from all of the articles were examined for additional cases (Table 1) . Clinical characteristics, immunosuppressive regimens, laboratory findings, diagnostic testing, B19V therapy and outcomes, including our case, are presented in Table 1 . The mean age (±SD) was 37.2 ± 21.8 years. Fifty percent of the cases were female. The mean hemoglobin level (±SD) before diagnosis was 5.91 ± 1.08 g/dL. In cases, in which information was available, the reticulocyte count was low; anemia was most often transfusion dependent; diagnosis was frequently made by PCR in peripheral blood and/or bone marrow specimens and by immunohistochemistry in bone marrow biopsy; IVIG was given to 11 cases with good outcome in all of them. In three cases, treatment with IVIG was not required. Serologies for B19V IgG and IgM were performed in 11 cases, B19V IgM was positive in six cases, suggesting acute infection.
| D ISCUSS I ON
Heart transplantation is the gold standard treatment for end-stage heart disease refractory to medical therapy, with a median survival of more than 12 years. 20 B19V depends on the surface P-antigen receptor for cellular entry. However, it appears that for complete cellular invasion, two additional co-receptors (α5 β1 integrin and Ku80) are required. 4, 24, 25 The P-antigen receptor is primarily found in erythroid progenitor cells often leading to hematological complications in healthy individuals and immunocompromised patients including transient aplastic crisis, red cell aplasia, or transfusion-dependent anemia.
There is no specific method for viral isolation from clinical spec- The majority of individuals with transfusion-dependent anemia secondary to B19V post-heart transplantation initially report fatigue and malaise. 13 Hemoglobin levels below 8 g/dL were reported in all cases ( Table 1) . Half of the patients presented with anemia refractory to multiple blood transfusions that, upon diagnosis of BV19 infection and treatment with IVIG, led to resolution of the anemia.
Notably, in three cases, spontaneous recovery of B19V-induced anemia occurred after epoetin alfa, iron supplementation, and blood transfusions. It is possible that in these three patients, lack of the P-antigen receptor ("phenotype p" blood type) played a role in their ability to recover spontaneously. Individuals with "phenotype p" have been studied since its discovery in 1951. In the absence of the P receptor, B19V ceases its ability to hemagglutinate erythrocytes.
Therefore, it has been hypothesized that people with this variation could be naturally immune to B19V. 26 In 
